ROIV
Roivant Sciences Ltd
NASDAQ: ROIV · HEALTHCARE · BIOTECHNOLOGY
$27.52
-0.90% today
Updated 2026-04-29
Market cap
$19.70B
P/E ratio
—
P/S ratio
1,479.80x
EPS (TTM)
$-1.17
Dividend yield
—
52W range
$11 – $30
Volume
5.5M
Roivant Sciences Ltd (ROIV) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+3.1%
Last 4 quarters
Revenue YoY growth
-77.8%
Most recent quarter
EPS YoY growth
-91.1%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+10.5%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+30.9%
2026-02-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-06 | $-0.38 | -22.6% | $21.14 | $27.67 | +30.9% |
| 2025-11-10 | $-0.17 | +46.9% | $20.62 | $20.90 | +1.4% |
| 2025-08-06 | $-0.25 | -1.6% | $11.63 | $11.55 | -0.7% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.31 | $-0.38 | -22.6% | $2.00M | -77.8% |
| 2025-09-30 | $-0.32 | $-0.17 | +46.9% | $1.57M | -64.9% |
| 2025-06-30 | $-0.25 | $-0.25 | -1.6% | $2.17M | -72.8% |
| 2025-03-31 | $-0.26 | $-0.29 | -10.3% | $7.57M | -16.1% |
| 2024-12-31 | $-0.24 | $-0.20 | +17.2% | $9.02M | -42.1% |
| 2024-09-30 | $-0.26 | $-0.31 | -20.4% | $4.47M | +22.7% |
| 2024-06-30 | $-0.26 | $0.12 | +146.2% | $7.99M | -63.1% |
| 2024-03-31 | $-0.30 | $-0.19 | +36.7% | $9.02M | -67.1% |
| 2023-12-31 | $-0.32 | $-0.30 | +6.3% | $15.56M | — |
| 2023-09-30 | $-0.31 | $-0.40 | -29.0% | $3.65M | — |
| 2023-06-30 | $-0.30 | $-0.38 | -26.7% | $21.62M | — |
| 2023-03-31 | $-0.36 | $-0.20 | +44.4% | $27.38M | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $-1.23 | $0.0B | +-65.5% | 8 | high |
| 2027 (E) | $-0.65 | $0.2B | +1750.0% | 8 | medium |
| 2028 (E) | $0.15 | $0.6B | +197.0% | 8 | medium |
| 2029 (E) | $0.85 | $0.9B | +67.0% | 8 | low |
| 2030 (E) | $1.42 | $1.3B | +39.0% | 8 | low |
Frequently asked questions
Has Roivant Sciences Ltd beaten earnings estimates?
Roivant Sciences Ltd has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +3.1% over the last 4 quarters.
How does ROIV stock react to earnings?
ROIV stock has moved an average of +10.5% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Roivant Sciences Ltd's revenue growth rate?
Roivant Sciences Ltd reported year-over-year revenue growth of -77.8% in its most recent quarter, with EPS growing -91.1% year-over-year.
What is the expected EPS for ROIV in 2026?
Analysts expect Roivant Sciences Ltd to report EPS of $-1.23 for fiscal year 2026, on revenue of $0.0B, based on estimates from 8 analysts.